The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, following nearly three ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Clearance of Lynkuet provides a new alternative to hormone-based treatment for hot flashes and sets up a market battle with ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

For biopharma, reaching the right patients at the right time is essential for both clinical and commercial success. The right ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...